

Andrea Sartore-Bianchi

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7554181/andrea-sartore-bianchi-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

164
papers

19,751
citations

48
h-index

140
g-index

198
ext. papers

23,290
ext. citations

8.9
avg, IF

6.08
L-index

#	Paper	IF	Citations
164	Detection of circulating tumor DNA in early- and late-stage human malignancies. <i>Science Translational Medicine</i> , 2014 , 6, 224ra24	17.5	2741
163	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. <i>Lancet Oncology, The</i> , 2010 , 11, 753-62	21.7	1653
162	Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5705-12	2.2	1358
161	Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. <i>Nature</i> , 2012 , 486, 532-6	50.4	1327
160	Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. <i>Lancet Oncology, The</i> , 2005 , 6, 279-86	21.7	833
159	Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. <i>Cancer Research</i> , 2007 , 67, 2643-8	10.1	708
158	A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. <i>Cancer Discovery</i> , 2011 , 1, 508-23	24.4	668
157	PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. <i>Cancer Research</i> , 2009 , 69, 1851-7	10.1	642
156	Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 304, 1812-20	27.4	580
155	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. <i>Nature Medicine</i> , 2015 , 21, 795-801	50.5	557
154	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 738-746	21.7	533
153	Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. <i>Cancer Discovery</i> , 2013 , 3, 658-73	24.4	489
152	Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). <i>Cancer Discovery</i> , 2017 , 7, 400-409	24.4	475
151	Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 1308-24	9.7	424
150	Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. <i>Cancer Discovery</i> , 2014 , 4, 1269-80	24.4	326
149	The genomic landscape of response to EGFR blockade in colorectal cancer. <i>Nature</i> , 2015 , 526, 263-7	50.4	310
148	Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3238-45	2.2	293

147	Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. <i>Nature</i> , 2017 , 552, 116-120	50.4	290
146	gene fusions as novel targets of cancer therapy across multiple tumour types. <i>ESMO Open</i> , 2016 , 1, e000023		289
145	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. <i>Cancer Discovery</i> , 2016 , 6, 147-153	24.4	255
144	Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. <i>PLoS ONE</i> , 2009 , 4, e7287	3.7	209
143	Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. <i>Science Translational Medicine</i> , 2014 , 6, 224ra26	17.5	203
142	Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. <i>Cancer Discovery</i> , 2016 , 6, 36-44	14.4	200
141	Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4217-9	2.2	191
140	The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. <i>Nature Communications</i> , 2015 , 6, 7002	17.4	178
139	Early-onset colorectal cancer in young individuals. <i>Molecular Oncology</i> , 2019 , 13, 109-131	7.9	173
138	Adaptive mutability of colorectal cancers in response to targeted therapies. <i>Science</i> , 2019 , 366, 1473-1480	9.3	148
137	Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. <i>Modern Pathology</i> , 2015 , 28, 1481-91	9.8	144
136	KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. <i>International Journal of Cancer</i> , 2013 , 133, 1259-65	7.5	141
135	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	126
134	Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. <i>Nature Communications</i> , 2016 , 7, 13665	17.4	121
133	Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. <i>Gut</i> , 2018 , 67, 1995-2005	19.2	119
132	BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. <i>Annals of Oncology</i> , 2015 , 26, 2092-7	10.3	110
131	Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. <i>Annals of Oncology</i> , 2018 , 29, 1108-1119	10.3	101
130	The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. <i>Molecular Oncology</i> , 2014 , 8, 1495-507	7.9	101

129	Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	94
128	Acquired resistance to EGFR-targeted therapies in colorectal cancer. <i>Molecular Oncology</i> , 2014 , 8, 1084-94	9.9	94
127	Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. <i>Annals of Oncology</i> , 2015 , 26, 1994-1999	10.3	93
126	Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer. <i>Clinical Cancer Research</i> , 2013 , 19, 2265-72	12.9	85
125	Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. <i>Clinical Cancer Research</i> , 2007 , 13, 5942-51	12.9	81
124	Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. <i>Cancer Cell</i> , 2018 , 34, 148-162.e7	24.3	77
123	Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis. <i>Clinical Colorectal Cancer</i> , 2017 , 16, e153-e163	3.8	70
122	Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. <i>Cancer Research</i> , 2016 , 76, 4504-15	10.1	63
121	Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer. <i>Journal of the National Cancer Institute</i> , 2014 , 106, djt322	9.7	58
120	Plasma HER2 () Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 3046-3053	12.9	58
119	Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer. <i>British Journal of Cancer</i> , 2015 , 113, 1730-4	8.7	57
118	Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 779-789	21.7	53
117	Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. <i>Lung Cancer</i> , 2005 , 48, 429-34	5.9	47
116	Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. <i>Annals of Oncology</i> , 2018 , 29, 119-126	10.3	46
115	HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2019 , 24, 1395-1402	5.7	45
114	Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2017 , 23, 3657-3666	12.9	44
113	Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies. <i>Cancer Treatment Reviews</i> , 2019 , 73, 41-53	14.4	44
112	EGFR FISH in colorectal cancer: what is the current reality?. <i>Lancet Oncology, The</i> , 2008 , 9, 402-3	21.7	38

111	A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. <i>Clinical Cancer Research</i> , 2020 , 26, 1372-1384	12.9	38
110	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2019 , 5, 1268-1275	13.4	37
109	Negative Hyperselection of Patients With and Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3099-3110	2.2	35
108	Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. <i>ESMO Open</i> , 2020 , 5, e000911	6	35
107	Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 80-83	3.8	34
106	Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , 2010 , 36 Suppl 3, S1-5	14.4	32
105	Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. <i>Clinical Colorectal Cancer</i> , 2019 , 18, e117-e129	3.8	32
104	Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory. <i>Annals of Oncology</i> , 2016 , 27, 1456-66	10.3	31
103	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study. <i>European Journal of Cancer</i> , 2019 , 118, 121-130	7.5	29
102	The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer. <i>Drugs</i> , 2019 , 79, 1375-1394	12.1	29
101	Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study. <i>Journal of Clinical Pathology</i> , 2012 , 65, 218-23	3.9	29
100	Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016 , 27, 1062-1067	10.3	28
99	Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. <i>Oncotarget</i> , 2015 , 6, 31604-12	3.3	27
98	The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer. <i>Annals of Oncology</i> , 2020 , 31, 1135-1147	10.3	27
97	A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell-Intrinsic Transcriptional MSI Traits. <i>Cancer Research</i> , 2019 , 79, 5884-5896	10.1	26
96	Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer. <i>Targeted Oncology</i> , 2010 , 5, 19-28	5	26
95	Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 6243-6259	12.9	25
94	Increased incidence of colon cancer among individuals younger than 50 years: A 17 years analysis from the cancer registry of the municipality of Milan, Italy. <i>Cancer Epidemiology</i> , 2019 , 60, 134-140	2.8	24

93	Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. <i>ESMO Open</i> , 2018 , 3, e000299	6	24
92	Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor. <i>Annals of Oncology</i> , 2017 , 28, 1302-1308	10.3	23
91	Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study. <i>Clinical Colorectal Cancer</i> , 2016 , 15, 213-21	3.8	23
90	Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study. <i>Cancer</i> , 2013 , 119, 3429-35	6.4	23
89	Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer. <i>Annals of Oncology</i> , 2005 , 16, 1848-9	10.3	23
88	Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3508-3508	2.2	23
87	Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System. <i>American Journal of Hypertension</i> , 2016 , 29, 158-62	2.3	22
86	Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. <i>European Journal of Cancer</i> , 2017 , 71, 43-50	7.5	22
85	The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. <i>British Journal of Cancer</i> , 2020 , 123, 403-409	8.7	22
84	Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020 , 19, 256-262.e2	3.8	22
83	Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study). <i>ESMO Open</i> , 2016 , 1, e000111	6	22
82	Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single-institution Phase II study. <i>Cancer</i> , 2004 , 100, 2132-8	6.4	21
81	Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3506-3506	2.2	21
80	Alka-372-001: First-in-human, phase I study of entrectinib in oral pan-trk, ROS1, and ALK inhibitor in patients with advanced solid tumors with relevant molecular alterations.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2517-2517	2.2	20
79	First-line FOLFOX plus panitumumab (Pan) followed by 5FU/LV plus Pan or single-agent Pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3505-3505	2.2	20
78	Combined Low Densities of FoxP3 and CD3 Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression. <i>Cancer Immunology Research</i> , 2019 , 7, 751-758	12.5	19
77	Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR. <i>Cancer Treatment Reviews</i> , 2016 , 51, 54-62	14.4	19
76	Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer. <i>PLoS ONE</i> , 2013 , 8, e62264	3.7	18

75	Liquid biopsy for rectal cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2019 , 79, 101893	14.4	17
74	High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib. <i>Frontiers in Oncology</i> , 2019 , 9, 622	5.3	17
73	Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2502-2502	2.2	17
72	Entrectinib for the treatment of metastatic NSCLC: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 333-341	3.5	16
71	Regorafenib in metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2014 , 14, 255-65	3.5	16
70	Optimal CD34(+) cell dose in autologous peripheral-blood stem-cell transplantation. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3319-20	2.2	16
69	Abstract CT005: Final results of the HERACLES trial in HER2-amplified colorectal cancer 2017 ,		16
68	HER2 amplification as a molecular bait for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: The HERACLES-RESCUE trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS774-TPS774	2.2	16
67	Human Epidermal Growth Factor Receptor 2 as a Molecular Biomarker for Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2018 , 4, 19-20	13.4	14
66	Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies. <i>Nature Communications</i> , 2018 , 9, 2287	17.4	14
65	Regorafenib for metastatic colorectal cancer. <i>Lancet, The</i> , 2013 , 381, 1537	4.0	14
64	Impact of inter-reader contouring variability on textural radiomics of colorectal liver metastases. <i>European Radiology Experimental</i> , 2020 , 4, 62	4.5	14
63	CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	14
62	Magnetic resonance imaging as an early indicator of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab. <i>Clinical Colorectal Cancer</i> , 2013 , 12, 45-53 ^{3,8}		12
61	Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients. <i>ESMO Open</i> , 2019 , 4,	6	12
60	The Evolutionary Landscape of Treatment for Mutant Metastatic Colorectal Cancer. <i>Cancers</i> , 2021 , 13,	6.6	12
59	The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review. <i>Frontiers in Oncology</i> , 2020 , 10, 533	5.3	11
58	Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience. <i>Targeted Oncology</i> , 2017 , 12, 525-533	5	11

57	Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy. <i>Cancer Discovery</i> , 2021 , 11, 1923-1937	24.4	10
56	Clonally expanded EOMES Tr1-like cells in primary and metastatic tumors are associated with disease progression. <i>Nature Immunology</i> , 2021 , 22, 735-745	19.1	10
55	Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer: Long-term Results of Treatment With Trastuzumab and Lapatinib. <i>JAMA Oncology</i> , 2020 , 6, 927-929	13.4	9
54	Linitis Plastica of the Rectum As a Clinical Presentation of Metastatic Lobular Carcinoma of the Breast. <i>Journal of Clinical Oncology</i> , 2016 , 34, e54-6	2.2	9
53	Cetuximab for treatment of metastatic colorectal cancer. <i>Annals of Oncology</i> , 2006 , 17 Suppl 7, vii66-7	10.3	9
52	TRKA expression and gene copy number across solid tumours. <i>Journal of Clinical Pathology</i> , 2018 , 71, 926-931	3.9	9
51	Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 1017-1024	12.9	8
50	Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS2659-TPS2659	22.8	8
49	Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities. <i>Cancer Treatment Reviews</i> , 2020 , 91, 102112	14.4	8
48	Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectal Cancer Enhanced Stratification).. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS3648-TPS3648	2.2	7
47	Radiomics predicts response of individual HER2-amplified colorectal cancer liver metastases in patients treated with HER2-targeted therapy. <i>International Journal of Cancer</i> , 2020 , 147, 3215-3223	7.5	7
46	Strategies to tackle RAS-mutated metastatic colorectal cancer. <i>ESMO Open</i> , 2021 , 6, 100156	6	7
45	Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study. <i>European Journal of Cancer</i> , 2020 , 135, 230-239	7.5	6
44	Toxicity of oxaliplatin rechallenge in metastatic colorectal cancer. <i>Annals of Oncology</i> , 2018 , 29, 2143-2146	4.3	6
43	Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity?. <i>Lung Cancer</i> , 2002 , 38, 159-62	5.9	6
42	Plasma HER2 (ERBB2) copy number to predict response to HER2-targeted therapy in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3506-3506	2.2	6
41	The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS4124-TPS4124	2.2	6
40	Epigenomic landscape of human colorectal cancer unveils an aberrant core of pan-cancer enhancers orchestrated by YAP/TAZ. <i>Nature Communications</i> , 2021 , 12, 2340	17.4	6

39	Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. <i>Cancers</i> , 2021 , 13,	6.6	6
38	Optimized EGFR Blockade Strategies in Addicted Gastroesophageal Adenocarcinomas. <i>Clinical Cancer Research</i> , 2021 , 27, 3126-3140	12.9	6
37	Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients. <i>Oncology Reports</i> , 2005 , 13, 689-95	3.5	5
36	Controversial evaluation of EGFR protein and gene status in predicting response to anti-EGFR monoclonal antibodies in metastatic colorectal cancer: a case report and review of the literature. <i>Targeted Oncology</i> , 2008 , 3, 127-130	5	4
35	Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer. <i>Annals of Oncology</i> , 2006 , 17 Suppl 2, ii49-51	10.3	4
34	Aspirin for colorectal cancer with PIK3CA mutations: the rising of the oldest targeted therapy?. <i>Annals of Translational Medicine</i> , 2013 , 1, 12	3.2	4
33	Germ cell tumors overexpress the candidate therapeutic target cyclin B1 independently of p53 function. <i>International Journal of Biological Markers</i> , 2015 , 30, e275-81	2.8	3
32	The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives.. <i>Cancer Treatment Reviews</i> , 2022 , 104, 102351	14.4	3
31	Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment.. <i>European Journal of Cancer</i> , 2021 , 163, 16-25	7.5	3
30	Abstract CT082: Pertuzumab and trastuzumab-emtansine in HER2-positive colorectal cancer: the HERACLES B trial 2016 ,		3
29	Breaking Barriers in HER2+ Cancers. <i>Cancer Cell</i> , 2020 , 38, 317-319	24.3	3
28	Liquid Biopsy for Small Cell Lung Cancer either De Novo or Transformed: Systematic Review of Different Applications and Meta-Analysis. <i>Cancers</i> , 2021 , 13,	6.6	3
27	The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 2505-2514	12.9	3
26	Therapeutic dual inhibition of HER2 pathway for metastatic colorectal cancer (mCRC): The HERACLES trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 565-565	2.2	2
25	Clinical prognostic score of BRAF V600E mutated (BM) metastatic colorectal cancer (mCRC): Results from the BRAF, BeCool platform.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 639-639	2.2	2
24	Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management.. <i>ESMO Open</i> , 2021 , 7, 100338	6	2
23	Clonal evolution and - coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer. <i>ESMO Open</i> , 2016 , 1, e000079	6	2
22	Concurrent Small-Cell Transformation and Emergence of -C797S and T790M Mutations Under Sequential Treatment With EGFR Inhibitors in Lung Adenocarcinoma.. <i>JCO Precision Oncology</i> , 2019 , 3, 1-5	3.6	2

21	Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA. <i>Targeted Oncology</i> , 2021 , 16, 309-324	5	2
20	Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patients. <i>Oncology Reports</i> , 2004 , 12, 855-9	3.5	2
19	ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series.. <i>JCO Precision Oncology</i> , 2022 , 6, e2200015	3.6	2
18	Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer. <i>Handbook of Experimental Pharmacology</i> , 2018 , 249, 145-159	3.2	1
17	Molecular Markers Beyond Microsatellite Instability for Assessing Prognosis in Early-Stage Colorectal Cancer: What Happens at Relapse?. <i>JAMA Oncology</i> , 2017 , 3, 481-482	13.4	1
16	Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET). <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018 , 43, 114-116	2.2	1
15	Is Codon 13 KRAS Mutation Biologically Different from Codon 12 Mutation?. <i>Current Colorectal Cancer Reports</i> , 2012 , 8, 272-276	1	1
14	Phase II study of temozolomide (TMZ) in metastatic colorectal cancer (mCRC) patients molecularly selected by MGMT promoter hypermethylation.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 583-583	2.2	1
13	Clinicopathological characteristics and HER2 status in metastatic colorectal cancer patients: Results of a diagnostic model development study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 581-581	2.2	1
12	A randomized phase II trial of second-line CAPTEM versus FOLFIRI in MGMT methylated, RAS mutated metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3509-3509 ^{2.2}	2.2	1
11	Personalized therapeutic strategies in HER2-driven gastric cancer. <i>Gastric Cancer</i> , 2021 , 24, 897-912	7.6	1
10	Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	1
9	The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2019 , 5, 1510-1511	13.4	0
8	Response: Re: Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 573-575	9.7	0
7	Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study.. <i>Oncologist</i> , 2022 , 27, e29-e36	5.7	0
6	Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients.. <i>European Journal of Cancer</i> , 2022 ,	7.5	0
5	Epidermal Growth Factor Receptor-Targeted Therapy of Colorectal Cancer with Panitumumab. <i>Current Cancer Therapy Reviews</i> , 2007 , 3, 249-254	0.4	
4	Efficacy of retreatment with oxaliplatin-based regimens in metastatic colorectal cancer patients: The RETROX-CRC retrospective study.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 127-127	2.2	

- 3 Mutational signatures of early-onset colorectal cancer.. *Journal of Clinical Oncology*, **2019**, 37, e15113-e15113
- 2 Radiomics features on CT scans to predict response to HER2-targeted therapy of hepatic metastases from colorectal cancer.. *Journal of Clinical Oncology*, **2019**, 37, e15086-e15086 2.2
- 1 The FUNNEL: A molecular multiplex triage for precision medicine in metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2016**, 34, TPS3636-TPS3636 2.2